Photo credit: www.investing.com
LifeMD Introduces New Men’s Hormone Therapy with TestoRx
LifeMD, Inc. (Nasdaq: LFMD), a prominent player in the realm of virtual primary care, has unveiled its latest offering under the Rex MD brand: TestoRx, a direct-to-consumer telehealth service focused on men’s hormone therapy. This innovative service includes an initial consultation and required blood tests to assess patients, followed by a range of treatment options designed to address low testosterone levels. These options encompass both hormone replacement therapy and alternative treatments aimed at boosting the body’s own hormone production, complemented by ongoing telehealth consultations and follow-up care.
Rex MD has established itself as a trusted men’s telehealth platform, providing accessible virtual medical solutions for various health concerns such as erectile dysfunction, premature ejaculation, hair loss, and more recently, weight management. The launch of TestoRx marks a significant expansion in Rex MD’s offerings, further catering to its rapidly growing patient base. Since its launch in 2019, the platform has successfully assisted around 500,000 individuals with their men’s health needs.
Justin Schreiber, Chairman and CEO of LifeMD, expressed enthusiasm for the new testosterone therapy program, highlighting that it was developed in collaboration with esteemed clinicians in the field. “We have created a compliant and multifaceted protocol aimed at men experiencing clinically low testosterone. Our objective is to provide men with an easy and cost-effective way to enhance their hormonal health from the comfort of their homes,” Schreiber stated.
The prevalence of male hypogonadism—a condition characterized by insufficient production of testosterone—is significant, particularly among older men, obese individuals, and those with type 2 diabetes. The Endocrine Society reports that nearly 35% of men over 45 and 30-50% of those suffering from obesity or type 2 diabetes may have this condition. Further insights from Rex MD’s anonymized data suggest that around 20% of men self-report symptoms indicative of low testosterone levels.
With a strong foundation in treating erectile dysfunction, LifeMD recognizes the link between hypogonadism and sexual health issues, including erectile dysfunction. As obesity is often associated with lower testosterone levels, addressing weight management becomes a vital part of their service, specifically targeting this demographic through the new hormone therapy offering. “TestoRx is a clinically relevant addition to our comprehensive men’s health services,” added Dr. Anthony Puopolo, President of LifeMD Affiliated P.C.s.
About LifeMD
LifeMD stands at the forefront of virtual primary healthcare, facilitating telemedicine consultations and providing access to lab and pharmacy services across more than 200 different medical conditions, including men’s and women’s health, hormone therapy, and weight management. The company utilizes a unique digital care platform, an extensive network of medical professionals across the United States, and a dedicated patient care center to offer high-quality healthcare that is both accessible and affordable. For more information about their services, visit LifeMD.com.
Cautionary Note Regarding Forward-Looking Statements
This announcement contains forward-looking statements as defined under U.S. securities laws. Such statements may include expectations or predictions regarding future business performance, including potential revenues, financial results, or product offerings. Terminology suggesting future performance—such as “believe,” “expect,” “intend,” “should,” and similar terms—signals these forward-looking elements. However, the actual results could differ significantly due to various factors, including market conditions, regulatory challenges, and economic fluctuations. LifeMD does not undertake any obligation to update these statements, except as required by law.
Contact Information
Investor Contact
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact
Jessica Friedeman, Chief Marketing Officer
press@lifemd.com
Source
www.investing.com